89bio to Participate in Upcoming Investor Conferences
89bio (NASDAQ: ETNB), a clinical-stage biopharmaceutical company specializing in liver and cardiometabolic disease therapies, has announced its management team's participation in two major healthcare investor conferences in May 2025: 1.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
89bio (NASDAQ: ETNB), a clinical-stage biopharmaceutical company specializing in liver and cardiometabolic disease therapies, has announced its management team's participation in two major healthcare investor conferences in May 2025:
1. BofA Securities 2025 Health Care Conference - Fireside chat scheduled for Wednesday, May 14, 2025, at 1:40 PM ET
2. 2025 RBC Capital Markets Global Healthcare Conference - Fireside chat scheduled for Tuesday, May 20, 2025, at 9:30 AM ET
Both presentations will be available via webcast on 89bio's investor relations website, with replays accessible for approximately 30 days after each event.
Details
News Market Reaction – ETNB
The recorded move for ETNB in the trading session of this news was -1.03%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, May 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in the following investor conferences during the month of May:
BofA Securities 2025 Health Care Conference
Format: Fireside Chat
Date: Wednesday, May 14, 2025
Time: 1:40 PM ET
2025 RBC Capital Markets Global Healthcare Conference
Format: Fireside Chat
Date: Tuesday, May 20, 2025
Time: 9:30 AM ET
The webcast of the fireside chats will be accessible in the investor section of 89bio’s website. A replay of the webcasts will be available for approximately 30 days following each conference.
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is in Phase 3 trials for its lead candidate, pegozafermin, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis, including patients with compensated cirrhosis, and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.
Investor Contact:
Annie Chang
89bio, Inc.
investors@89bio.com
PJ Kelleher
LifeSci Advisors, LLC
617-430-7579
pkelleher@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.